Publikationen von Marcus Ising
Alle Typen
Zeitschriftenartikel (290)
61.
Zeitschriftenartikel
15, 126 (2015)
Analyzing pathways from childhood maltreatment to internalizing symptoms and disorders in children and adolescents (AMIS): a study protocol. BMC PSYCHIATRY 62.
Zeitschriftenartikel
168 (4), S. 274 - 283 (2015)
ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis. AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS 63.
Zeitschriftenartikel
65, S. 166 - 171 (2015)
Poor sleep quality is associated with impaired glucose tolerance in women after gestational diabetes. JOURNAL OF PSYCHIATRIC RESEARCH 64.
Zeitschriftenartikel
25 (6), S. 864 - 872 (2015)
IGF-I in major depression and antidepressant treatment response. EUROPEAN NEUROPSYCHOPHARMACOLOGY 65.
Zeitschriftenartikel
55, S. 102 - 115 (2015)
Identification and characterization of HPA-axis reactivity endophenotypes in a cohort of female PTSD patients. PSYCHONEUROENDOCRINOLOGY 66.
Zeitschriftenartikel
5, e538 (2015)
RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. Translational psychiatry 67.
Zeitschriftenartikel
279, S. 46 - 49 (2015)
MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene. JOURNAL OF NEUROIMMUNOLOGY 68.
Zeitschriftenartikel
18 (4), S. 1 - 9 (2015)
FKBP5 Genotype-Dependent DNA Methylation and mRNA Regulation After Psychosocial Stress in Remitted Depression and Healthy Controls. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 69.
Zeitschriftenartikel
18 (2), S. 199 - 209 (2015)
Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. NATURE NEUROSCIENCE 70.
Zeitschriftenartikel
8 (404), S. ra119 - ra119 (2015)
Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. Science signaling 71.
Zeitschriftenartikel
40 (2), S. 361 - 371 (2015)
XRCC5 as a Risk Gene for Alcohol Dependence: Evidence from a Genome-Wide Gene-Set-Based Analysis and Follow-up Studies in Drosophila and Humans. NEUROPSYCHOPHARMACOLOGY 72.
Zeitschriftenartikel
76 (6), S. e802 - e808 (2015)
Clinical risk factors for weight gain during psychopharmacologic treatment of depression: results from 2 large German observational studies. The Journal of clinical psychiatry 73.
Zeitschriftenartikel
16 (7), S. 689 - 701 (2015)
CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. PHARMACOGENOMICS 74.
Zeitschriftenartikel
82 (1), S. 106 - 114 (2015)
Specific behaviour, mood and personality traits may contribute to obesity in patients with craniopharyngioma. CLINICAL ENDOCRINOLOGY 75.
Zeitschriftenartikel
103, S. 267 - 275 (2014)
Increased HPA axis response to psychosocial stress in remitted depression: the influence of coping style. BIOLOGICAL PSYCHOLOGY 76.
Zeitschriftenartikel
11 (11), e1001755 (2014)
Association of FKBP51 with Priming of Autophagy Pathways and Mediation of Antidepressant Treatment Response: Evidence in Cells, Mice, and Humans. PLOS MEDICINE 77.
Zeitschriftenartikel
49, S. 229 - 243 (2014)
Mice selected for extremes in stress reactivity reveal key endophenotypes of major depression: A translational approach. PSYCHONEUROENDOCRINOLOGY 78.
Zeitschriftenartikel
76 (7), S. E15 - E17 (2014)
Blood Mononuclear Cell Proteome Suggests Integrin and Ras Signaling as Critical Pathways for Antidepressant Treatment Response. BIOLOGICAL PSYCHIATRY 79.
Zeitschriftenartikel
165 (5), S. 428 - 437 (2014)
Genetic Relationships Between Suicide Attempts, Suicidal Ideation and Major Psychiatric Disorders: A Genome-Wide Association and Polygenic Scoring Study. AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS 80.
Zeitschriftenartikel
17 (3), S. 240 - 245 (2014)
The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas. PITUITARY